AESTHETIC MEDICAL (PAIYY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2024, filed Apr 25, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PAIYY SEC filings page.
AESTHETIC MEDICAL (PAIYY) reported $103.5M in revenue for fiscal year 2024, up 7.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
AESTHETIC MEDICAL does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
AESTHETIC MEDICAL passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
AESTHETIC MEDICAL reported a net loss of $2.7M while generating $10.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
AESTHETIC MEDICAL generated $103.5M in revenue in fiscal year 2024. This represents an increase of 7.7% from the prior year.
AESTHETIC MEDICAL reported a net loss of $2.7M in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
AESTHETIC MEDICAL earned -$0.02 per diluted share (EPS) in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2024.
Cash & Balance Sheet
AESTHETIC MEDICAL generated $6.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 150.7% from the prior year.
AESTHETIC MEDICAL held $5.9M in cash against $1.9M in long-term debt as of fiscal year 2024, with $55.1M of liabilities due within a year.
Not reported for fiscal year 2024.
Margins & Returns
AESTHETIC MEDICAL's gross margin was 44.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 2.5 percentage points from the prior year.
AESTHETIC MEDICAL's net profit margin was -2.6% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2.8 percentage points from the prior year.
AESTHETIC MEDICAL's ROE was -65.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 11.1 percentage points from the prior year.
Not reported for fiscal year 2024.
Capital Allocation
AESTHETIC MEDICAL invested $4.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 46.1% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
PAIYY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.5M+7.7% | $96.1M-1.0% | $97.2M-4.1% | $101.3M-26.7% | $138.2M+10.7% | $124.8M+12.7% | $110.7M+3.3% | $107.2M |
| Cost of Revenue | $57.3M+12.7% | $50.8M+11.4% | $45.6M-22.7% | $59.0M+7.9% | $54.7M+38.0% | $39.6M+5.4% | $37.6M+4.3% | $36.0M |
| Gross Profit | $46.3M+2.0% | $45.4M-12.0% | $51.6M+21.9% | $42.3M-49.3% | $83.5M-2.0% | $85.2M+16.5% | $73.1M+2.8% | $71.1M |
| Interest Expense | $409K-35.6% | $635K-64.6% | $1.8M+74.8% | $1.0M+86.1% | $552K+189.4% | $191K-85.8% | $1.3M+32.9% | $1.0M |
| Income Tax | $3.3Mn/m | -$2.1Mn/m | -$2.6Mn/m | -$1.9Mn/m | -$1.9M-195.7% | $2.0M-25.1% | $2.7M-9.1% | $3.0M |
| Net Income | -$2.7Mn/m | -$5.3Mn/m | -$11.1Mn/m | -$92.1Mn/m | -$36.1M-284.3% | $19.6Mn/m | -$37.1Mn/m | -$11.8M |
| EPS (Basic) | -$0.02n/m | -$0.04 | -$0.13n/m | -$1.40n/m | -$0.55-230.1% | $0.43n/m | -$0.90n/m | -$0.29 |
| EPS (Diluted) | -$0.02n/m | -$0.04 | -$0.13n/m | -$1.40n/m | -$0.55n/m | -$0.11n/m | -$0.90n/m | -$0.29 |
| Diluted Shares (Avg) | 144M+9.0% | 132M | 82M+24.2% | 66M+1.0% | 65M+11.1% | 59M+43.2% | 41M+0.1% | 41M |
Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses, Operating Income, EBITDA.
PAIYY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $66.6M-15.6% | $79.0M-0.3% | $79.2M-12.5% | $90.5M-43.1% | $159.1M+5.8% | $150.4M+52.9% | $98.4M | N/A |
| Current Assets | $12.1M-23.2% | $15.7M+39.7% | $11.3M-36.9% | $17.8M-43.5% | $31.6M-16.9% | $38.0M-7.6% | $41.2M | N/A |
| Cash & Equivalents | $5.9M-33.2% | $8.8M+398.0% | $1.8M-71.4% | $6.2M-9.4% | $6.8M-69.3% | $22.2M+49.8% | $14.8M-8.5% | $16.2M |
| Inventory | $2.0M-6.9% | $2.2M-45.7% | $4.0M-15.8% | $4.8M-6.1% | $5.1M+36.2% | $3.8M+22.0% | $3.1M | N/A |
| Accounts Receivable | $2.5M-17.4% | $3.1M-18.7% | $3.8M | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $5.0M-3.5% | $5.2M-3.9% | $5.4M-7.5% | $5.8M-81.7% | $31.9M+26.8% | $25.2M+155.9% | $9.8M+3.7% | $9.5M |
| Total Liabilities | $65.3M-12.0% | $74.2M-23.8% | $97.5M-18.6% | $119.8M+27.6% | $93.8M+43.1% | $65.6M-51.3% | $134.7M | N/A |
| Current Liabilities | $55.1M-4.9% | $57.9M-26.5% | $78.8M-7.2% | $85.0M+83.8% | $46.2M+21.3% | $38.1M+53.0% | $24.9M | N/A |
| Non-Current Liabilities | $10.3M-37.1% | $16.3M-12.5% | $18.6M-46.5% | $34.8M-26.9% | $47.6M+73.3% | $27.5M-75.0% | $109.8M | N/A |
| Long-Term Debt | $1.9M-57.5% | $4.4M+4.8% | $4.2M-65.3% | $12.2M+4.7% | $11.6M+527.2% | $1.9M-35.8% | $2.9M | N/A |
| Total Equity | $4.2M-39.4% | $6.9Mn/m | -$16.5Mn/m | -$24.6M-141.0% | $59.9M-23.8% | $78.6Mn/m | -$40.5Mn/m | -$3.4M |
| Retained Earnings | -$164.1Mn/m | -$165.9Mn/m | -$165.4Mn/m | -$167.0Mn/m | -$73.2Mn/m | -$34.8Mn/m | -$54.4M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
PAIYY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.9M+4.3% | $10.5Mn/m | -$10.9M-235.9% | $8.0Mn/m | -$129K-101.0% | $12.5M+1650.8% | $712K-94.0% | $11.8M |
| Capital Expenditures | $4.2M-46.1% | $7.8M+3260.5% | $232K-95.6% | $5.2M-11.3% | $5.9M-40.8% | $9.9M+50.0% | $6.6M-9.3% | $7.3M |
| Free Cash Flow | $6.7M+150.7% | $2.7Mn/m | -$11.1M-497.0% | $2.8Mn/m | -$6.0M-337.0% | $2.5Mn/m | -$5.9M-230.4% | $4.5M |
| Investing Cash Flow | -$4.2Mn/m | -$7.4M-1731.4% | $451Kn/m | -$1.8Mn/m | -$19.5Mn/m | -$16.4Mn/m | -$11.1Mn/m | -$10.6M |
| Financing Cash Flow | -$9.4M-329.4% | $4.1M-38.0% | $6.6Mn/m | -$7.1M-361.7% | $2.7M-76.3% | $11.4M+17.7% | $9.7Mn/m | -$4.3M |
| Share Buybacks | N/A | N/A | N/A | N/A | $304K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid.
PAIYY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.7%-2.5pp | 47.2%-5.9pp | 53.1%+11.3pp | 41.7%-18.7pp | 60.4%-7.8pp | 68.3%+2.2pp | 66.0%-0.3pp | 66.4% |
| Net Margin | -2.6%+2.8pp | -5.5%+5.9pp | -11.4%+79.5pp | -90.9%-64.8pp | -26.1%-41.8pp | 15.7%+49.2pp | -33.5%-22.5pp | -11.0% |
| Return on Equity | -65.5%+11.1pp | -76.6% | N/A | N/A | -60.2%-85.1pp | 24.9% | N/A | N/A |
| Return on Assets | -4.1%+2.6pp | -6.7%+7.3pp | -14.0%+87.7pp | -101.7%-79.0pp | -22.7%-35.7pp | 13.0%+50.8pp | -37.7% | N/A |
| Current Ratio | 0.22-0.1x | 0.27+0.1x | 0.14-0.1x | 0.21-0.5x | 0.68-0.3x | 1.00-0.7x | 1.65 | N/A |
| Debt-to-Equity | 0.45-0.2x | 0.64 | N/A | N/A | 0.19+0.2x | 0.02 | N/A | N/A |
| Liabilities-to-Equity | 15.66+4.9x | 10.78 | N/A | N/A | 1.57+0.7x | 0.83 | N/A | N/A |
| Asset Turnover | 1.55+0.3x | 1.220.0x | 1.23+0.1x | 1.12+0.3x | 0.870.0x | 0.83-0.3x | 1.13 | N/A |
| FCF Margin | 6.5%+3.7pp | 2.8%+14.2pp | -11.5%-14.2pp | 2.8%+7.1pp | -4.3%-6.4pp | 2.0%+7.4pp | -5.3%-9.6pp | 4.2% |
Not reported in any period shown, so not listed: Operating Margin.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AESTHETIC MEDICAL PAIYY | FY2024 | $103.5M | -$2.7M | -2.6% | $599K | — |
| BIOCORRX INC NEW BICX | FY2025 | $797K | -$3.4M | N/A | $6.3M | — |
Where AESTHETIC MEDICAL Ranks
Frequently Asked Questions
What is AESTHETIC MEDICAL's annual revenue?
AESTHETIC MEDICAL (PAIYY) reported $103.5M in total revenue for fiscal year 2024. This represents a 7.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AESTHETIC MEDICAL's revenue growing?
AESTHETIC MEDICAL (PAIYY) revenue grew by 7.7% year-over-year, from $96.1M to $103.5M in fiscal year 2024.
Is AESTHETIC MEDICAL profitable?
No, AESTHETIC MEDICAL (PAIYY) reported a net loss of $2.7M in fiscal year 2024, with a net profit margin of -2.6%.
How much debt does AESTHETIC MEDICAL have?
As of fiscal year 2024, AESTHETIC MEDICAL (PAIYY) had $5.9M in cash and equivalents against $1.9M in long-term debt.
What is AESTHETIC MEDICAL's gross margin?
AESTHETIC MEDICAL (PAIYY) had a gross margin of 44.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is AESTHETIC MEDICAL's net profit margin?
AESTHETIC MEDICAL (PAIYY) had a net profit margin of -2.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is AESTHETIC MEDICAL's return on equity (ROE)?
AESTHETIC MEDICAL (PAIYY) has a return on equity of -65.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is AESTHETIC MEDICAL's free cash flow?
AESTHETIC MEDICAL (PAIYY) generated $6.7M in free cash flow during fiscal year 2024. This represents a 150.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AESTHETIC MEDICAL's operating cash flow?
AESTHETIC MEDICAL (PAIYY) generated $10.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are AESTHETIC MEDICAL's total assets?
AESTHETIC MEDICAL (PAIYY) had $66.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are AESTHETIC MEDICAL's capital expenditures?
AESTHETIC MEDICAL (PAIYY) invested $4.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is AESTHETIC MEDICAL's current ratio?
AESTHETIC MEDICAL (PAIYY) had a current ratio of 0.22 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is AESTHETIC MEDICAL's debt-to-equity ratio?
AESTHETIC MEDICAL (PAIYY) had a debt-to-equity ratio of 0.45 as of fiscal year 2024. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is AESTHETIC MEDICAL's liabilities-to-equity ratio?
AESTHETIC MEDICAL (PAIYY) had a liabilities-to-equity ratio of 15.66 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is AESTHETIC MEDICAL's return on assets (ROA)?
AESTHETIC MEDICAL (PAIYY) had a return on assets of -4.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is AESTHETIC MEDICAL's P/E ratio?
AESTHETIC MEDICAL (PAIYY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $599K as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AESTHETIC MEDICAL's price-to-sales ratio?
AESTHETIC MEDICAL (PAIYY) trades at 0.0x sales, its market capitalization divided by $103.5M revenue, FY2024. The market capitalization is $599K as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AESTHETIC MEDICAL's Piotroski F-Score?
AESTHETIC MEDICAL (PAIYY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AESTHETIC MEDICAL's earnings high quality?
AESTHETIC MEDICAL (PAIYY) reported a net loss of $2.7M while generating $10.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.